Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13416632 | 1.00 | PIK3CD (0.52) | PIK3CDLMNACYP2C9DPP4DPP8 | |
| SCHEMBL15932157 | 1.00 | PIK3CD (0.52) | PIK3CDLMNACYP2C9DPP4DPP8 | |
| SCHEMBL19701893 | 1.00 | PIK3CD (0.52) | PIK3CDLMNACYP2C9DPP4DPP8 | |
| SCHEMBL890066 | 1.00 | PIK3CD (0.52) | PIK3CDLMNACYP2C9DPP4DPP8 | |
| SCHEMBL15314559 | 0.84 | PIK3CD (0.41) | PIK3CDLMNACYP2C9DPP4DPP8 | |
| SCHEMBL13291299 | 0.81 | PIK3CD (0.38) | PIK3CDLMNACYP2C9 | |
| SCHEMBL10155038 | 0.79 | PIK3CD (0.38) | PIK3CDLMNACYP2C9 | |
| SCHEMBL24087110 | 0.77 | LMNA (0.43) | PIK3CDLMNACYP2C9DPP4 | |
| SCHEMBL29979450 | 0.77 | LMNA (0.43) | PIK3CDLMNACYP2C9DPP4 | |
| SCHEMBL26431392 | 0.77 | PIK3CD (0.36) | PIK3CDLMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20140221332-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355707-A1 | BICYCLIC HETEROARYL AMINE COMPOUNDS | PIK3R3, JAK2, JAK3 | PIK3CD 14/4885LMNA 3651/4885CYP2C9 1309/4885 |
| US-20140221332-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | GRM5, GRIK5, GRM2 | PIK3CD 2687/4885LMNA 4870/4885CYP2C9 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.